Analysts have been eager to weigh in on the Healthcare sector with new ratings on Mainz Biomed B.V. (MYNZ – Research Report) and Check-Cap (CHEK – Research Report).
Mainz Biomed B.V. (MYNZ)
JonesTrading analyst Justin Walsh maintained a Buy rating on Mainz Biomed B.V. today and set a price target of $11.00. The company’s shares closed last Thursday at $2.95, close to its 52-week low of $2.93.
According to TipRanks.com, Walsh has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on Mainz Biomed B.V. is a Moderate Buy with an average price target of $10.50.
See Insiders’ Hot Stocks on TipRanks >>
Check-Cap (CHEK)
H.C. Wainwright analyst Yi Chen reiterated a Hold rating on Check-Cap today. The company’s shares closed last Thursday at $2.32, close to its 52-week low of $1.22.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on Check-Cap is currently a Hold rating.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MYNZ:
- Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
- Mainz Biomed launches ColoAlert with Marylebone Laboratory in the UK
- Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
- Mainz Biomed enters commercial partnership with Fugene Genetics for ColoAlert
- Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
